Here's Why Regeneron (REGN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jun 12, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Jun 11, 2026

REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $REGN--REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm.

Business Wire • Jun 10, 2026

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and promising pipeline assets. EYLEA HD U.S. sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA franchise. Recent FDA approvals and pending regulatory decisions for EYLEA HD and CEMDISIRAN provide near-term catalysts and franchise durability.

Seeking Alpha • Jun 8, 2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 8, 2026

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026.

GlobeNewsWire • Jun 4, 2026

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

Zacks Investment Research • Jun 4, 2026

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.

Zacks Investment Research • Jun 1, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 1, 2026

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • May 29, 2026